Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Future of GA Treatment
Scientists are closer than ever to new therapies for geographic atrophy, an advanced form of the eye disease called dry age-related macular degeneration. (Source: WebMD Health)
Source: WebMD Health - March 10, 2023 Category: Consumer Health News Source Type: news

Three vitamins that could help protect against vision loss - prevent macular degeneration
Age-related macular degeneration is a common condition that most often affects people in their 50s and 60s - and can lead to complete vision loss in extreme cases. (Source: Daily Express - Health)
Source: Daily Express - Health - March 6, 2023 Category: Consumer Health News Source Type: news

The effects of age and central field loss on maintaining balance control when stepping up to a new level under time-pressure - Zult T, Timmis MA, Pardhan S.
OBJECTIVE: To investigate the effects of age and central field loss on the landing mechanics and balance control when stepping up to a new level under time-pressure. METHODS: Eight older individuals with age-related macular degeneration (AMD), eigh... (Source: SafetyLit)
Source: SafetyLit - March 3, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Amsler Grid Not Sensitive Enough for Diagnosing Neovascular AMD
MONDAY, Feb. 27, 2023 -- The Amsler grid has a sensitivity of 67 percent for diagnosing neovascular age-related macular degeneration (AMD) compared with healthy controls, according to a systematic review and meta-analysis published online Feb. 16 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2023 Category: Pharmaceuticals Source Type: news

FDA Approves First Treatment for Geographic Atrophy
FRIDAY, Feb. 24, 2023 -- Pegcetacoplan (SYFOVRE) has been approved by the U.S. Food and Drug Administration as the first and only treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration. Pegcetacoplan is an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 24, 2023 Category: General Medicine Source Type: news

FDA Approves First Treatment for Geographic Atrophy, Pegcetacoplan (SYFOVRE)
FRIDAY, Feb. 24, 2023 -- Pegcetacoplan (SYFOVRE) has been approved by the U.S. Food and Drug Administration as the first and only treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration. Pegcetacoplan is an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 24, 2023 Category: General Medicine Source Type: news

Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
; Draft Guidance for Industry; Availability (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 24, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First Treatment for Geographic Atrophy Secondary to AMD
(MedPage Today) -- The FDA approved pegcetacoplan injection (Syfovre) as the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), according to a statement from Apellis Pharmaceuticals. Primary support... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 18, 2023 Category: American Health Source Type: news

New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Investor Update - February 10, 2023 Category: Pharmaceuticals Source Type: news

New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Media News - February 10, 2023 Category: Pharmaceuticals Source Type: news

U.S. Adults Lack Knowledge About Age-Related Macular Degeneration
WEDNESDAY Feb. 8, 2023 -- Most U.S. adults are unaware of warning signs of age-related macular degeneration (AMD) and treatment advances for the condition, according to survey results released by the American Society of Retina Specialists. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news

Recognizing National Glaucoma Awareness Month
January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease. Glaucoma refers to a group of eye diseases that can cause vision loss or blindness due to damage of the optic nerve. It is one of the leading causes of irreversible blindness in the United States. High intraocular pressure (IOP) is a common risk factor for glaucoma, which over time causes stress on the optic nerve and can lead to gradual vision loss. While there currently is no available cure, the condition can be treated and ...
Source: The Catalyst - February 1, 2023 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Medicines in Development Patients R & D Focus Source Type: news

How age-related macular degeneration blurs vision
Age-related macular degeneration is a common cause of age-related vision loss. It's the No. 1 cause of vision loss for adults over age 50. It affects the retina, particularly the macula, a portion of the retina with specialized cells that allow you your sharpest vision. Your retina consists of layers of neural tissue that line the back part of the eye that sends information from the eyes to the brain. Just like a baseball diamond… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 27, 2023 Category: Databases & Libraries Source Type: news